[HTML][HTML] FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
…, C Delbaldo, E Assenat, B Chauffert… - New England journal …, 2011 - Mass Medical Soc
Background Data are lacking on the efficacy and safety of a combination chemotherapy
regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as …
regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as …
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
…, D Cathelin, C Garrido, B Chauffert… - European journal of …, 2004 - Wiley Online Library
We investigated the mechanisms of immune tolerance raised by tumors by comparing
immunogenic and tolerogenic tumor cell clones isolated from a rat colon carcinoma. When …
immunogenic and tolerogenic tumor cell clones isolated from a rat colon carcinoma. When …
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
…, E Solary, A Le Cesne, L Zitvogel, B Chauffert - Cancer immunology …, 2007 - Springer
CD4 + CD25 + regulatory T cells are involved in the prevention of autoimmune diseases and
in tumor-induced tolerance. We previously demonstrated in tumor-bearing rodents that one …
in tumor-induced tolerance. We previously demonstrated in tumor-bearing rodents that one …
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised …
…, TP Cescon, K Chan, A Chaudhry, B Chauffert… - The Lancet, 2019 - thelancet.com
Background There are few effective treatment options for patients with recurrent or metastatic
head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and …
head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and …
Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4+CD25+ regulatory T cell proliferation
…, E Solary, G Kroemer, F Martin, B Chauffert… - The Journal of …, 2005 - rupress.org
The mechanisms through which regulatory T cells accumulate in lymphoid organs of tumor-bearing
hosts remain elusive. Our experiments indicate that the accumulation of CD4 + CD25 …
hosts remain elusive. Our experiments indicate that the accumulation of CD4 + CD25 …
Iron‐dependent cell death of hepatocellular carcinoma cells exposed to sorafenib
…, JC Barbare, JC Mazière, B Chauffert… - … journal of cancer, 2013 - Wiley Online Library
The multikinase inhibitor sorafenib is currently the treatment of reference for advanced
hepatocellular carcinoma (HCC). In our report, we examined the cytotoxic effects of sorafenib on …
hepatocellular carcinoma (HCC). In our report, we examined the cytotoxic effects of sorafenib on …
Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T …
…, L Apetoh, B Coudert, F Martin, B Chauffert… - Clinical cancer …, 2008 - AACR
Purpose: T-cell infiltration is associated with good tumor prognosis in many cancers. To assess
the capacity of neoadjuvant chemotherapy to affect T-cell infiltration in breast cancer, we …
the capacity of neoadjuvant chemotherapy to affect T-cell infiltration in breast cancer, we …
The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells
…, D Chatelain, V Debuysscher, JC Barbare, B Chauffert… - Cancer letters, 2015 - Elsevier
Sorafenib is the treatment of reference for advanced hepatocellular carcinoma (HCC), the
most frequent form of primary liver tumour. The loss of function of the retinoblastoma (Rb) …
most frequent form of primary liver tumour. The loss of function of the retinoblastoma (Rb) …
Is stenting as “a bridge to surgery” an oncologically safe strategy for the management of acute, left-sided, malignant, colonic obstruction? A comparative study with a …
…, O Brehant, E Bartoli, F Mauvais, B Chauffert… - Annals of …, 2013 - journals.lww.com
Methods: From January 1998 to June 2011, we retrospectively identified patients operated
on for LMCO with curative intent. The primary outcome criterion was overall survival. Short-…
on for LMCO with curative intent. The primary outcome criterion was overall survival. Short-…
HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs
…, A Fromentin, A Hammann, AP Arrigo, B Chauffert… - Cancer research, 1997 - AACR
Resistance of colorectal cancer cells to chemotherapeutic drugs increases as cells reach
confluence. Here we show that the small stress protein HSP27, which has been described to …
confluence. Here we show that the small stress protein HSP27, which has been described to …